Postopeative moderate-to-severe pain
Conditions
Interventions
Tegileridine group (Group T):Ten minutes before the end of the operation, 0.5 mg of Tegileridinel was injected intravenously. Postoperatively, PCIA analgesia was provided (0.1 mg/kg of Tegileridine to
Oliceridine group (Group O):Ten minutes before the end of the operation, 1 mg of Oliceridine was injected intravenously. Postoperatively, PCIA analgesia was provided (0.2 mg/kg of Oliceridine to 200 m
Sufentanil group (Group S):Ten minutes before the end of the operation, 5ug of Sufentanil was injected intravenously. Postoperatively, PCIA analgesia was provided (1 µg/kg of Sufentanil to 200 ml), wi
Sponsors
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Hospitalized patients aged >=65 years old, male or female; (2) For elective laparoscopic urological surgery under general anesthesia, the estimated operation time was 1h-4 hours; (3) Tracheal intubation under general anesthesia, ASA classification I-III; New York Heart Association (NYH) class I-II (4) 18kg/m2<= body mass index (BMI)<=30kg/m2; (5) The subjects fully understood the purpose, content, process and risks of the trial, voluntarily participated in the clinical trial and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) patients with preoperative MMSE score =28kg/m2; (6) preoperative PaO2 < 60 mmHg or SpO2 < 90%; (7) patients with acute or severe bronchial asthma, chronic obstructive pulmonary disease or pulmonary heart disease; (8) use of opioid agonist/antagonist or other drug/treatment affecting analgesia within 24h before randomization (or within 5 half-lives of the drug label); "These include, but are not limited to, ketorolac tromethamine injection, ibuprofen, acetaminophen or other non-steroidal anti-inflammatory drugs (NSAIDs), monoamine oxidase inhibitors, glucocorticoids (except topical and inhaled drugs), and sedatives."
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate-to-severe pain;Sleep quality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of analgesic pump presses;Quality of postoperative recovery, Qor-15;The time of the first exhaust;Adverse reaction incidence;The usage of drug in the analgesic pump ;Pain score (VAS); | — |
Countries
China
Contacts
Public ContactSijia Chen
Central Hospital of Dalian University of Technology(Dalian Municipal Central Hospital)
Outcome results
None listed